SINGAPORE - Biotechnology firm Moderna has committed to investing in Singapore and the region, with plans to grow its Asia-Pacific headcount from 80 to 200 by the end of 2023.
On Monday, the American company announced its new Singapore general manager, Ms Evelyn Pang, who will head and grow its Singapore office. She will be setting up a team to oversee a range of functions to support commercial and medical activities in the market.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
